Boston Scientific lifts revenue guidance as numbers beat Wall Street consensus
Boston Scientific Corp. (NYSE:BSX) was on the rise Wednesday after posting first-quarter results that beat expectations. The Marlborough, Mass.-based company also reported that it was raising its 2018 revenue guidance range to $9.75 billion to $9.9 billion, up from a predicted $9.65 billion to $9.8 billion. The company closed at $29.42 after opening at $28.35.
Data for Heartmate 3 LVAD suggest the need for a study against transplants
ORLANDO, Fla. Some devices are just the latest and best in class while others force clinicians to revisit long-held assumptions about the possibilities of a device type. This appears to be the case with an interim report of data from a study of the Heartmate 3 device, which not only handily bested the Heartmate II for freedom from disabling stroke at two years, but also prompted one observer to ask whether the time has come to try a left ventricular assist device against transplantation.
Radiologists say time has come to grapple with promise of AI, big data
The twin tools of artificial intelligence and big data have proven more cumbersome than anticipated to apply to several fields of endeavor, but a new article in the Journal of the American College of Radiology says radiologists and by implication, device makers must begin now to sort through the challenges presented by these instruments if diagnostic imaging is to become a 21st century science.